There are currently 1146 clinical trials in Cincinnati, Ohio looking for participants to engage in research studies. Trials are conducted at various facilities, including Cincinnati Children's Hospital Medical Center, University of Cincinnati, University of Cincinnati Medical Center and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis
NCT04880187
Recruiting
This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving fat and inflammation (steatohepatitis) as well as fibrosis in subjects with non alcoholic steatohepatitis (NASH). as well as the safety and tolerability of AXA1125. Subjects will take one of two different doses of AXA1125 or a placebo twice daily, and a liver biopsy will be done at the beginning and end of the 48-week study.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/07/2022
Locations: Consultants for Clinical Research, Cincinnati, Ohio
Conditions: Non Alcoholic Steatohepatitis (NASH)
Register for Updates
A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors
NCT04843709
Recruiting
The objective of this study is to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of MRG004A in patients with Tissue Factor positive advanced or metastatic solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/06/2022
Locations: The Christ Hospital Cancer Center, Cincinnati, Ohio
Conditions: Advanced or Metastatic Solid Tumors
Register for Updates
Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations
NCT05050149
Recruiting
This study evaluates the safety and efficacy of PTX-022 (sirolimus) Topical Gel 3.9% w/w in the treatment of Microcystic Lymphatic Malformations. The participant will receive 3 months of PTX-022 treatment by the end of the study.
Gender:
All
Ages:
13 years and above
Trial Updated:
08/26/2022
Locations: Cincinnati Children's Hospital, Cincinnati, Ohio
Conditions: Microcystic Lymphatic Malformation
Register for Updates
Diagnostic Accuracy and Safety of DBV1605 for the Diagnosis of Non-IgE Mediated Cow's Milk Allergy in Children
NCT04492683
Recruiting
Study to assess the diagnostic accuracy (sensitivity, specificity, positive and negative predictive value) of DBV1605 for the diagnosis of non-Immunoglobulin E (IgE) mediated cow's milk allergy (CMA) in children with symptoms suggestive of non-IgE mediated CMA.
Gender:
All
Ages:
Between 29 days and 24 months
Trial Updated:
08/09/2022
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Cow's Milk Allergy
Register for Updates
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
NCT04502394
Recruiting
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia. Participants must be relapsed/refractory (having failed prior therapy)
Gender:
All
Ages:
18 years and above
Trial Updated:
08/03/2022
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
Register for Updates
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer
NCT05486143
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy. Condition or disease: Breast Cancer Intervention/treatment: Drug: Gedatolisib Drug: Palbociclib Drug: Fulvestrant Drug: Alpelisib Phase 3
Gender:
All
Ages:
18 years and above
Trial Updated:
08/02/2022
Locations: Bon Secours Mercy Health, Cincinnati, Ohio
Conditions: Breast Cancer
Register for Updates
Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
NCT02013336
Recruiting
This is a Phase 1 study of the combination of two drugs: MM-398 and Cyclophosphamide. The goal is to find the highest dose of MM-398 that can be given safely when it is used together with the chemotherapy drug Cyclophosphamide.
Gender:
All
Ages:
Between 12 months and 20 years
Trial Updated:
03/17/2022
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Recurrent or Refractory Solid Tumors, Ewing Sarcoma, Rhabdomyosarcoma, Neuroblastoma, Osteosarcoma
Register for Updates
Prospective Global Registry for the Study of Chronic Total Occlusion Intervention
NCT02061436
Recruiting
Percutaneous coronary intervention (PCI) of chronic total occlusions (CTOs) is increasingly being performed in patients with advanced coronary artery disease, but there is limited information on the techniques utilized and the procedural outcomes. The goal of this multicenter, investigator initiated registry is to collect information on treatment strategies and outcomes of consecutive patients undergoing CTO PCI among various participating centers. The information collected will be used to deter... Read More
Gender:
All
Ages:
All
Trial Updated:
03/08/2022
Locations: The Christ Hospital Ohio Heart & Vascular, Cincinnati, Ohio
Conditions: Coronary Artery Disease
Register for Updates
KINCISE™ Surgical Automated System in Total Hip Arthroplasty (THA)
NCT05223777
Recruiting
There is a growing interest in the effects of mental health and wellness on orthopedic intervention outcomes, not only in terms of how advances in surgical procedures influence patient outcomes, but also with regard for physician physical and mental well-being. Although total hip arthroplasty (THA) is associated with favorable clinical outcomes as assessed by surgeon evaluation, radiographic analysis and implant longevity, unfavorable long-term pain and quality of life outcomes are consistently... Read More
Gender:
All
Ages:
21 years and above
Trial Updated:
01/24/2022
Locations: Univrsity of Cincinnati Medical Center, Cincinnati, Ohio
Conditions: Osteoarthritis, Hip
Register for Updates
Safety and Durability of Sirolimus for Treatment of LAM
NCT02432560
Recruiting
The MIDAS study aims to follow LAM patients who are currently taking, have previously failed or been intolerant of, or may (at some time in the future) take mTOR inhibitors (sirolimus or everolimus) as part of their clinical care. Adult female TSC patients may also enroll, with or without lung cysts.
Gender:
Female
Ages:
18 years and above
Trial Updated:
01/11/2022
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Lymphangioleiomyomatosis
Register for Updates
Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®
NCT01908192
Recruiting
The purpose of this study is to determine if NaBen® is a safe and effective add-on treatment for schizophrenia in adolescents.
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
09/10/2021
Locations: University of Cincinnati - Dept. of Psychiatry and Behavioral Neuroscience, Cincinnati, Ohio
Conditions: Schizophrenia
Register for Updates
Observational Study to Compare Outcomes of Different Psychiatric Treatment of Suicidal Adolescents
NCT04625686
Recruiting
To address the unmet need of optimizing the treatment and management for adolescent suicidality, the investigators propose to evaluate the effectiveness and safety of telehealth services compared to inpatient and OCIC for suicidal adolescents in target population. To achieve this goal, the investigators propose a multi- site study to compare telehealth, OCIC, and inpatient care, and see which can lead to a lower risk of a suicidal event (primary outcome) as well as higher treatment satisfaction... Read More
Gender:
All
Ages:
Between 12 years and 18 years
Trial Updated:
04/26/2021
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Suicidal Ideation
Register for Updates